Arcutis Biotherapeutics Inc (ARQT) - News Archive

: Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatit...

Arcutis Biotherapeutics Inc., a leading dermatology-focused biopharmaceutical company, has recently submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) to expand...

Harnessing Talent: Arcutis Biotherapeutics Strategic Stock Unit Grants as a Recruitment CatalystIn the competitive world of biotechnology, where innovation and talent acquisition are key drivers of success, Arcutis Biot...

Arcutis Biotherapeutics Grants Inducement Awards Under Nasdaq Rule 5635(c)(4): A Strategic Move for Empowering New TalentWestlake Village, Calif. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a renowned commercial-stage...

In a significant announcement made on January 6, 2025, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a company dedicated to pioneering advancements in immuno-dermatology, unveiled the issuance of 75,500 restricted stock...

Arcutis Biotherapeutics Strengthens Workforce Through Strategic Stock Incentives, Reflecting Confidence in Future GrowthWESTLAKE VILLAGE, Calif. Dec. 06, 2024 In a strategic move that underscores confidence in its ongoi...

Arcutis Biotherapeutics Enriches Talent Portfolio with Inducement Grants, Aiming for Sustained Shareholder Value Amidst Stock Fluctuations WESTLAKE VILLAGE, Calif. Nov. 4, 2024 Arcutis Biotherapeutics, Inc. (Nasdaq: ARQ...

Arcutis Biotherapeutics Announces Inducement Grants: A Strategic Move to Bolster GrowthWESTLAKE VILLAGE, Calif. October 4, 2024 In the competitive world of biopharmaceuticals, talent acquisition often plays a crucial ro...

Arcutis Biotherapeutics, Inc. has made groundbreaking strides in dermatology with their novel medication, ZORYVE (Roflumilast) Cream 0.15%. This cream has shown promising results from the recently pooled subgroup analys...

In a significant advancement for dermatology, Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental New Drug Application (sNDA) for ZORYVE (roflumilast)...

Arcutis Announces Groundbreaking Results for ZORYVE in the Treatment of Mild to Moderate Atopic Dermatitis WESTLAKE VILLAGE, Calif. Sept. 19, 2024 Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a rising star in the realm...

Transformative Advances in Dermatologic Therapies: Arcutis Emerging Leadership in Alopecia Areata and Atopic DermatitisThe landscape of dermatologic treatments is ever-evolving, with significant advancements capturing t...

: Atopic dermatitis (AD), a prevalent inflammatory skin condition in pediatrics, presents unique challenges in treatment, especially in young children. This article reviews the long-term safety and efficacy results from...

WESTLAKE VILLAGE, Calif., Aug. 02, 2024 - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a leading biopharmaceutical company specializing in immuno-dermatology, announced today the issuance of 38,000 restricted stock uni...

Arcutis Biotherapeutics: A Game-Changer in Dermatology with Dual FDA ApprovalsArcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a company that prides itself on pioneering advancements in immuno-dermatology, is making signif...

Arcutis Biotherapeutics Inc Shares Struggle Amidst Strong YTD PerformanceArcutis Biotherapeutics Inc shares have faced a challenging year, trailing behind the overall market performance. However, despite this recent set...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., July 03, 2024 - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a leading biopharmaceutical company specializ...

Arcutis Pharmaceuticals recently unveiled promising data from the INTEGUMENT-OLE long-term open-label study, evaluating the efficacy of investigational once-daily roflumilast cream 0.15% in the treatment of mild to mode...

Arcutis Biotherapeutics, a leading biopharmaceutical company specializing in immuno-dermatology advancements, recently announced the granting of 57,500 restricted stock units to six newly recruited employees. These indu...

Arcutis Unveils New Research at Industry Conference: Implications for Dermatological Conditions : Arcutis Biotherapeutics, Inc., a leading biopharmaceutical company dedicated to providing innovations in the treatment of...